1973 Volume 20 Issue 1 Pages 93-104
Epsilon-aminocaproic acid (EACA) has been used clinically on patients with ruptured aneurysm to prevent rebleeding before operation, but it is thought to increase the incidence of ischemic cerebral infarction as a side effect. In order to dissolve this dilemma, the authors undertook an experimental study showing how the combined administration of EACA and heparin modifies the experimentally induced arterial thrombus and the antifibrinolytic activity in the rat. Ninety-six rats were divided into three groups: EACA-heparin, EACA and control. EACA was administered orally 0.8 g/kg/day from one day before the ligation of the abdominal aorta, and heparin was injected subcutaneously 800 u/kg at first and then 400 u/kg every 12 hours. Autopsy was done on the 4th, 9th and 14th day after ligation. (Results) l. EACA plays a significant role in preserving the thrombus weight. 2. The side effect of heparin was not recognized in this study. 3. In the EACA-heparin group, the antifibrinolytic as well as the anticoagulant effect of the agents seemed to be well preserved. The combined administration of antifibrinolytic agent and heparin prevents possibly the rebleeding without ischemic cerebral infarction in the treatment of ruptured aneurysm.
